drugset / Trial / NCT03663582

Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

NCT03663582

Phase 3 Completed 7 enrolled Shire
NaSingle-groupOpen-labelTreatment

Summary

The objectives of this clinical study are to evaluate the safety, efficacy, and pharmacokinetics (PK) of teduglutide in Japanese participants with short bowel syndrome (SBS) who are dependent on parenteral nutrition/intravenous (PN/IV) over a 24-week treatment period.

Timeline

Start
2018-07-06
Primary completion
2019-08-06
Completion
2019-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Teduglutide Peptide 0.05 mg/kg Subcutaneous

Indications